Prolonged survival of composite facial allografts in non-human primates associated with posttransplant lymphoproliferative disorder

Transplantation

Volumn 88, Issue 11, 2009, Pages 1242-1250

  Barth, Rolf N ^a   Nam, Arthur J ^a   Stanwix, Matthew G ^a   Kukuruga, Debra ^a   Drachenberg, Cinthia I ^a   Bluebond Langner, Rachel ^a   Hui Chou, Helen ^a   Shipley, Steven T ^a   Bartlett, Stephen T ^a   Rodriguez, Eduardo D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Composite tissue allotransplantation; Face transplant; Non human primate; Posttransplant lymphoproliferative disorder; Tacrolimus

Indexed keywords

ALLOANTIBODY; RAPAMYCIN; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ALLOGRAFT; ALLOTRANSPLANTATION; ANEMIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPOSITE GRAFT; CONTROLLED STUDY; GENOTYPE; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BLOOD; BONE MARROW TRANSPLANTATION; DISEASE MODEL; DRUG EFFECT; FACIAL TRANSPLANTATION; GENETICS; GRAFT REJECTION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MACACA; MALE; MIXED LYMPHOCYTE CULTURE; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK FACTOR; TIME;

ANIMALS; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; FACIAL TRANSPLANTATION; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; ISOANTIBODIES; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOPROLIFERATIVE DISORDERS; MACACA FASCICULARIS; MAGNETIC RESONANCE IMAGING; MALE; RISK FACTORS; SIROLIMUS; TACROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 73349140870     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c1b6d0     Document Type: Article

References (49)

1. International Registry on Hand and Composite Tissue Transplantation. Available at: http://www.handregistry com. Accessed October 27, 2009.
2. Dubernard JM, Lengele B, Morelon E, et al. Outcomes 18 months after the first human partial face transplantation. N Engl J Med 2007; 357: 2451.
3. Devauchelle B, Badet L, Lengele B, et al. First human face allograft: Early report. Lancet 2006; 368: 203.
4. Guo S, Han Y, Zhang X, et al. Human facial allotransplantation: A 2-year follow-up study. Lancet 2008; 372: 631.
5. Dubernard JM, Owen E, Herzberg G, et al. Human hand allograft: Report on first 6 months. Lancet 1999; 353: 1315.
6. Dubernard JM, Owen E, Lefrancois N, et al. First human hand transplantation. Case report. Transpl Int 2000; 13(suppl 1): S521.
7. Jones JW, Gruber SA, Barker JH, et al. Successful hand transplantation. One-year follow-up Louisville Hand Transplant Team. N Engl J Med 2000; 343: 468.
8. Jones JW Jr, Ustuner ET, Zdichavsky M, et al. Long-term survival of an extremity composite tissue allograft with FK506-mycophenolate mofetil therapy. Surgery 1999; 126: 384.
9. Schneeberger S, Ninkovic M, Gabl M, et al. First forearm transplantation: Outcome at 3 years. Am J Transplant 2007; 7: 1753.
10. Arslan E, Klimczak A, Siemionow M. Chimerism induction in vascu-larized bone marrow transplants augmented with bone marrow cells. Microsurgery 2007; 27: 190.
11. Ozmen S, Ulusal BG, Ulusal AE, et al. Composite vascularized skin/ bone transplantation models for bone marrow-based tolerance studies. Ann Plast Surg 2006; 56: 295.
12. Siemionow M, Ulusal BG, Ozmen S, et al. Composite vascularized skin/ bone graft model: A viable source for vascularized bone marrow transplantation. Microsurgery 2004; 24: 200.
13. Siemionow M, Klimczak A, Unal S, et al. Hematopoietic stem cell en-graftment and seeding permits multi-lymphoid chimerismin vascular-ized bone marrow transplants. Am J Transplant 2008; 8: 1163.
14. Mathes DW, Randolph MA, Solari MG, et al. Split tolerance to a composite tissue allograft in a swine model. Transplantation 2003; 75: 25.
15. Cendales LC, Xu H, Bacher J, et al. Composite tissue allotransplanta- tion: Development of a preclinical model in nonhuman primates. Transplantation 2005; 80: 1447.
16. Ustuner ET, Zdichavsky M, Ren X, et al. Long-term composite tissue allograft survival in a porcine model with cyclosporine/mycophenolate mofetil therapy. Transplantation 1998; 66: 1581.
17. Barth RN, Bluebond-Langner R, Nam A, et al. Facial subunit composite tissue allografts in nonhuman primates: I. Technical and immunosup-pressive requirements for prolonged graft survival. Plast Reconstr Surg 2009; 123: 493.
18. Silverman RP, Banks ND, Detolla LJ, et al. Aheterotopic primate model for facial composite tissue transplantation. Ann Plast Surg 2008; 60: 209.
19. Cendales LC, Kanitakis J, SchneebergerS, et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am J Transplant 2008; 8: 1396.
20. Vagefi P, Barth RN, Yamamoto S, et al. Thymic dependent long-term acceptance of renal allografts in juvenile baboons treated with a short course of FK506. Am J Transplant 2003; 3: 316.
21. Nam AJ, Stanwix MG, Rodriguez ED, et al. Tacrolimus monotherapy as strategy for prolonged composite tissue allograft survival in a non-human primate model [abstract]. J Am Coll Surg 2008; 207: S105.
22. Chadburn A, Suciu-Foca N, Cesarman E, et al. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Pathol 1995; 147: 1862.
23. Gulley ML, Swinnen LJ, Plaisance KT Jr, et al. Tumor origin and CD20 expressionin posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: Implications for immune-based therapy. Transplantation 2003; 76: 959.
24. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol He-matol 2005; 56: 155.
25. Dharnidharka VR, Araya CE. Post-transplant lymphoproliferative disease. Pediatr Nephrol 2009; 24: 731.
26. Dharnidharka VR, Tejani AH, Ho PL, et al. Post-transplant lympho-proliferative disorder in the United States: Young Caucasian males are at highest risk. Am J Transplant 2002; 2: 993.
27. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphopro-liferation after bone marrow transplantation. Blood 1988; 72: 520.
28. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999; 94: 2208.
29. Juvonen E, Aalto SM, Tarkkanen J, et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplanta- tionasaconsequence ofintensive immunosuppressive treatment. Bone Marrow Transplant 2003; 32: 97.
30. Huang CA, Fuchimoto Y, Gleit ZL, et al. Posttransplantation lympho-proliferative disease in miniature swine after allogeneic hematopoietic cell transplantation: Similarity to human PTLD and association with a porcine gammaherpesvirus. Blood 2001; 97: 1467.
31. Talpe S, Oike F, Dehoux JP, et al. Posttransplant lymphoproliferative disorder after liver transplantation in miniature swine. Transplantation 2001; 71: 1684.
32. Schmidtko J, Wang R, Wu CL, et al. Posttransplant lymphoprolifera-tive disorder associated with an Epstein-Barr-related virus in cynomol-gus monkeys. Transplantation 2002; 73: 1431.
33. Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lympho-proliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233.
34. Utsugi R, Barth RN, Lee RS, et al. Induction of transplantation tolerance with a short course of tacrolimus (FK506): I. Rapid and stable tolerance to two-haplotype fully MHC-mismatched kidney allografts in miniature swine. Transplantation 2001; 71: 1368.
35. Denny WB, Prapapanich V, Smith DF, et al. Structure-function analysis of squirrel monkey FK506-binding protein 51, a potent inhibitor of glucocorticoid receptor activity. Endocrinology 2005; 146: 3194.
36. Shapiro R, Ellis D, Tan HP, et al. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr 2006; 148: 813.
37. Tan HP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006; 6: 2409.
38. Shapiro R, Jordan ML, Basu A, et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 2003; 238: 520.
39. Vakiani E, Basso K, Klein U, et al. Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. Hematol Oncol 2008; 26: 199.
40. Kaleem Z, Hassan A, Pathan MH, et al. Flow cytometric evaluation of posttransplant B-cell lymphoproliferative disorders. Arch Pathol Lab Med 2004; 128: 181.
41. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353.
42. Baumeister S, Kleist C, Dohler B, et al. Risks of allogeneic hand transplantation. Microsurgery 2004; 24: 98.
43. Bordea C, Wojnarowska F, Millard PR, et al. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004; 77: 574.
44. Cooney WP, Hentz VR. Hand transplantation\-primum non nocere. J Hand Surg Am 2002; 27: 165.
45. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741.
46. Morris PJ, Bradley JA, Doyal L, et al. Facial transplantation: A working party report from the Royal CollegeofSurgeonsofEngland. Transplantation 2004; 77: 330.
47. Ong CS, Keogh AM, Kossard S, et al. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999; 40: 27.
48. Siemionow M, Demir Y, Mukherjee A, et al. Development and maintenance of donor-specific chimerism in semi-allogeneic and fully major histocompatibility complex mismatched facial allograft transplants. Transplantation 2005; 79: 558.
49. Lee WP, Yaremchuk MJ, Pan YC, et al. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg 1991; 87: 401.